Enfuvirtide (Fuzeon)

Published March 17, 2003; Updated September 21, 2007
Susa Coffey, MD
Selected Reference
9. Greenberg ML, Melby T, Sista P, DeMasi R, Cammack N, Salgo M, Whitcomb J, Petropoulos C, Matthews TJ. Baseline and on-treatment susceptibility to Enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks. 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003, Boston. Abstract 141.